Background Interstitial pneumonia in connective tissue diseases (CTD-IP) featuring
inflammation and fibrosis is a leading cause of death in CTD-IP patients. The related …

Abstract Background Mesenchymal stromal cells (MSCs) are a potential therapeutic tool for
pulmonary fibrosis. However, ex vivo MSC expansion using serum poses risks of harmful …

During acute or chronic lung injury, inappropriate immune response and/or aberrant repair
process causes irreversible damage in lung tissue and most usually results in the …

Pulmonary fibrosis is a progressive lung disease that its pathogenic mechanism currently is
incompletely understood. Toll-like receptor (TLR) signaling has recently been identified as a …

Background T helper 17 cells (Th17)/regulatory T cells (Treg), as subtypes of CD4+ T cells,
play an important role in the inflammatory response of acute respiratory distress syndrome …

Methods Human AD-MSCs were administered intravenously on day 3, 6 and 9 after an intra-
tracheal challenge with bleomycin, whereas, pirfenidone was given orally in drinking water …

Interstitial lung diseases (ILDs) are a heterogeneous group of diseases characterized by
varying degrees of inflammation and fibrosis of the pulmonary interstitium. The interrelations …

Background aims Rheumatoid arthritis (RA) is characterized by an overactive immune
system, with limited treatment options beyond immunosuppressive drugs or biological …

The regenerative and immunomodulatory characteristics of mesenchymal stem cells (MSCs)
make them attractive in the treatment of many diseases. Although they have shown …

Idiopathic pulmonary fibrosis (IPF) is one of the most aggressive forms of idiopathic
interstitial pneumonias, characterized by chronic and progressive fibrosis subverting the …